128 related articles for article (PubMed ID: 32403069)
1. Alemtuzumab and prescription medication use in the MS population.
Chertcoff A; Ng HS; Zhu F; Zhao Y; Kingwell E; Tremlett H
Mult Scler Relat Disord; 2020 Jul; 42():102086. PubMed ID: 32403069
[TBL] [Abstract][Full Text] [Related]
2. Severe B cell-mediated disease activation despite two cycles of alemtuzumab in a patient with multiple sclerosis.
Hyun JW; Kim Y; Kim G; Kim SH; Kim HJ
Mult Scler; 2019 Dec; 25(14):1942-1945. PubMed ID: 30403365
[TBL] [Abstract][Full Text] [Related]
3. Mild COVID-19 infection in a patient with multiple sclerosis and severe depletion of T-lymphocyte subsets due to alemtuzumab.
Guevara C; Villa E; Cifuentes M; Naves R; Grazia J
Mult Scler Relat Disord; 2020 Sep; 44():102314. PubMed ID: 32593959
[No Abstract] [Full Text] [Related]
4. Early beginning of alemtuzumab: Changing the multiple sclerosis treatment paradigm. Interim analysis of the LEMVIDA study.
Meca-Lallana JE; Álvarez-Cermeño JC; Casanova Estruch B; Izquierdo Ayuso G; Ortiz Castillo R; Rodríguez-Antigüedad A; Calles Hernández C;
Neurologia (Engl Ed); 2024 Jun; 39(5):383-391. PubMed ID: 37116693
[TBL] [Abstract][Full Text] [Related]
5. Marked neutropenia: Significant but rare in people with multiple sclerosis after alemtuzumab treatment.
Baker D; Giovannoni G; Schmierer K
Mult Scler Relat Disord; 2017 Nov; 18():181-183. PubMed ID: 29141806
[TBL] [Abstract][Full Text] [Related]
6. Polypharmacy and patterns of prescription medication use among cancer survivors.
Murphy CC; Fullington HM; Alvarez CA; Betts AC; Lee SJC; Haggstrom DA; Halm EA
Cancer; 2018 Jul; 124(13):2850-2857. PubMed ID: 29645083
[TBL] [Abstract][Full Text] [Related]
7. Multiple sclerosis: structural and functional integrity of the visual system following alemtuzumab therapy.
Wang C; Barton J; Kyle K; Ly L; Barnett Y; Hartung HP; Reddel SW; Beadnall H; Taha M; Klistorner A; Barnett MH
J Neurol Neurosurg Psychiatry; 2021 Dec; 92(12):1319-1324. PubMed ID: 34187865
[TBL] [Abstract][Full Text] [Related]
8. Alemtuzumab as rescue therapy in case of multiple sclerosis rebound following Natalizumab break: Clinical case and literature review.
Federle L; Puthenparampil M; Stenta G; Paolo G; Francesco P
Mult Scler Relat Disord; 2019 May; 30():262-264. PubMed ID: 30851640
[TBL] [Abstract][Full Text] [Related]
9. Neutropenia with fatal outcome in a multiple sclerosis patient 23 days after alemtuzumab infusion.
Yiannopoulou KG; Papadimitriou D; Anastasiou AI; Siakantaris M
Mult Scler Relat Disord; 2018 Jul; 23():15-16. PubMed ID: 29730587
[TBL] [Abstract][Full Text] [Related]
10. [Change of therapeutic algorithm in sclerosis multiplex based on two case reports].
Biernacki T; Bencsik K; Kincses ZT; Sandi D; Fricska-Nagy Z; Faragó P; Vécsei L
Ideggyogy Sz; 2017 Nov; 70(11-12):381-387. PubMed ID: 29870646
[TBL] [Abstract][Full Text] [Related]
11. Myasthenia gravis following alemtuzumab therapy for multiple sclerosis.
Midaglia L; Gratacòs M; Caronna E; Raguer N; Sastre-Garriga J; Montalban X; Tintoré M
Neurology; 2018 Sep; 91(13):622-624. PubMed ID: 30143565
[No Abstract] [Full Text] [Related]
12. Repopulation of T, B, and NK cells following alemtuzumab treatment in relapsing-remitting multiple sclerosis.
Gilmore W; Lund BT; Li P; Levy AM; Kelland EE; Akbari O; Groshen S; Cen SY; Pelletier D; Weiner LP; Javed A; Dunn JE; Traboulsee AL
J Neuroinflammation; 2020 Jun; 17(1):189. PubMed ID: 32539719
[TBL] [Abstract][Full Text] [Related]
13. Pneumonitis secondary to alemtuzumab in a patient with multiple sclerosis - A non-infectious cause of breathlessness.
Whiteside D; Barth S; Datta A; Trip SA
Mult Scler Relat Disord; 2018 May; 22():139-140. PubMed ID: 29684788
[TBL] [Abstract][Full Text] [Related]
14. Interrogation of the Multiple Sclerosis Prodrome Using High-Dimensional Health Data.
Zhao Y; Wijnands JMA; Högg T; Kingwell E; Zhu F; Evans C; Fisk JD; Marrie RA; Tremlett H
Neuroepidemiology; 2020; 54(2):140-147. PubMed ID: 31940638
[TBL] [Abstract][Full Text] [Related]
15. [Updated recommendations of the Council of Experts on the use and safety of alemtuzumab (Lemtrada)].
Khachanova NV; Bakhtiyarova KZ; Boyko AN; Vlasov YV; Davydovskaya MV; Evdoshenko EP; Zakharova MN; Kotov SV; Popova EV; Sivertseva SA; Totolyan NA; Khabirov FA
Zh Nevrol Psikhiatr Im S S Korsakova; 2020; 120(3):82-91. PubMed ID: 32323949
[TBL] [Abstract][Full Text] [Related]
16. Severe CNS inflammation after discontinuation of natalizumab and start of daclizumab successfully treated with alemtuzumab.
Hümmert MW; Deppe J; Pul R; Wurster U; Schwenkenbecher P; Sühs KW; Bronzlik P; Stangel M; Skripuletz T
Mult Scler Relat Disord; 2018 May; 22():87-89. PubMed ID: 29631243
[TBL] [Abstract][Full Text] [Related]
17. [Alemtuzumab therapy 2017].
Biernacki T; Bencsik K; Sandi D; Vécsei L
Ideggyogy Sz; 2017 Nov; 70(11-12):371-380. PubMed ID: 29870645
[TBL] [Abstract][Full Text] [Related]
18. Hepatic microabscesses during CMV reactivation in a multiple sclerosis patient after alemtuzumab treatment.
Barone S; Scannapieco S; Torti C; Filippelli E; Pisani V; Granata A; Console D; Demonte G; Tallarico T; Polidoro S; Quattrone A; Valentino P
Mult Scler Relat Disord; 2018 Feb; 20():6-8. PubMed ID: 29272733
[TBL] [Abstract][Full Text] [Related]
19. Sarcoidosis following alemtuzumab treatment for multiple sclerosis.
Willis MD; Hope-Gill B; Flood-Page P; Joseph F; Needham E; Jones J; Coles A; Robertson NP
Mult Scler; 2018 Nov; 24(13):1779-1782. PubMed ID: 30307364
[TBL] [Abstract][Full Text] [Related]
20. Acute leukocytosis during alemtuzumab treatment in patients with active relapsing-remitting multiple sclerosis.
Iovino A; Aruta F; Carotenuto A; Manganelli F; Iodice R
Mult Scler Relat Disord; 2019 Feb; 28():98-100. PubMed ID: 30580038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
